— Know what they know.
Not Investment Advice

MDGL NASDAQ

Madrigal Pharmaceuticals, Inc.
1W: +0.3% 1M: -2.9% 3M: +4.1% YTD: -13.8% 1Y: +75.9% 3Y: +74.7% 5Y: +285.7%
$513.07
+1.25 (+0.24%)
 
Weekly Expected Move ±6.1%
$460 $492 $524 $555 $587
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 43 · $11.8B mcap · 21M float · 1.66% daily turnover · Short 71% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$11.8B
52W Range265-615
Volume255,784
Avg Volume346,891
Beta-1.04
Dividend
Analyst Ratings
20 Buy 2 Hold 1 Sell
Consensus Buy
Company Info
CEOWilliam J. Sibold
Employees528
SectorHealthcare
IndustryBiotechnology
IPO Date2007-02-06
Four Tower Bridge
West Conshohocken, PA 19428
US
267 824 2827
About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Soergel David S-Sale 844 $515.90 2026-05-18
Dier Mardi S-Sale 646 $431.94 2026-03-06
Dier Mardi S-Sale 40 $425.08 2026-03-06
Dier Mardi S-Sale 420 $426.86 2026-03-06
Dier Mardi S-Sale 80 $427.85 2026-03-06

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms